Stock BOLT BOLT BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
0.75 USD +0.32% Intraday chart for Bolt Biotherapeutics, Inc. +0.01% -33.04%
05-20 Bolt Biotherapeutics, Inc. Announces Management Changes CI
05-20 Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Bolt Biotherapeutics, Inc. Announces Management Changes
Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes
Top Midday Decliners
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%
Top Premarket Decliners
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu
Bolt Biotherapeutics Insider Sold Shares Worth $128,993, According to a Recent SEC Filing
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
Bolt Biotherapeutics Begins Dosing in Advanced Cancers Phase 1/2 Study of BDC-3042
Sector Update: Health Care Stocks Rising in Late Afternoon Trading
Sector Update: Health Care Stocks Higher in Afternoon Trading
Bolt Biotherapeutics Says US FDA Granted Orphan Drug Designation for BDC-1001 for Gastric Cancer
Bolt Biotherapeutics Says Candidate Cancer Treatment Secures Patent
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BOLT Stock
  4. News Bolt Biotherapeutics, Inc.
  5. Other languages